Rituximab and hyaluronidase human

Indications and Usage

Rituximab and hyaluronidase human is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for the treatment of adult patients with:

• Follicular Lymphoma (FL)
  • Relapsed or refractory, follicular lymphoma as a single agent
  • Previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single agent maintenance therapy
  • Non-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy
• Diffuse Large B-cell Lymphoma (DLBCL)  
  • Previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens
• Chronic Lymphocytic Leukemia (CLL)  
  • Previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide (FC)

Limitations of Use:

• Initiate treatment with RITUXAN HYCELA only after patients have received at least one full dose of a rituximab product by intravenous infusion.
   

Side effects needing medical attention

Most common adverse reactions are:  

• FL: infections, neutropenia, nausea, constipation, cough, and fatigue
• DLBCL: infections, neutropenia, hair loss, nausea, and anemia
• CLL: infections, neutropenia, nausea, thrombocytopenia, fever, vomiting, and injection site erythema